Anticoagulation during pregnancy in patients with a prosthetic heart valve
Authors:
- Jose M. CastellanoJCJose M. Castellano
- Rajeev L. NarayanRNRajeev L. Narayan
- Prashant VaishnavaPVPrashant Vaishnava
- Valentin FusterVFValentin Fuster
- 15 May 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 9 (7) , 415-424
Abstract
Effective anticoagulation is mandatory for pregnant women with mechanical heart valves. Oral anticoagulants offer the best maternal protection against thrombosis, but their use might be associated with an appreciable risk of fetal malformations and pregnancy loss. By contrast, heparin derivatives are associated with a reduced risk of fetal damage, but an increased risk of valve thrombosis in the mother, even with appropriate dose adjustment and monitoring of therapeutic efficacy. Given the varying risks of available anticoagulation strategies, and the paucity of data to inform the optimal approach, no single accepted treatment option exists for pregnant women with mechanical prosthetic valves. Although low-molecular-weight heparin is considered more efficacious than unfractionated heparin, treatment failures, even at therapeutic levels of factor Xa inhibition, have been reported. The risk of warfarin-related embryopathy might be overstated, particularly at doses ≤ 5 mg daily. We advocate an individualized anticoagulation strategy that takes into account the patient's preferences, calls for the use of vitamin K antagonists throughout pregnancy (substituted with a heparin derivative only close to term) for those patients at the greatest risk of thromboembolism, and relies on close multidisciplinary collaboration between the cardiac and obstetric care teams.Keywords
This publication has 92 references indexed in Scilit:
- ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Use of Low Molecular Weight Heparin in Pregnant Women With Mechanical Heart ValvesThe American Journal of Cardiology, 2009
- Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experienceHaematologica, 2009
- Epidemiology and causes of preterm birthThe Lancet, 2008
- Comparative Pharmacokinetics of Vitamin K AntagonistsClinical Pharmacokinetics, 2005
- Pregnancy-Induced Changes in PharmacokineticsClinical Pharmacokinetics, 2005
- Pregnancy outcome in women with prosthetic heart valvesAmerican Journal of Obstetrics and Gynecology, 2004
- A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulationAmerican Journal of Obstetrics and Gynecology, 2004
- Durability of the hancock MO bioprosthesis compared with standard aortic valve bioprosthesesThe Annals of Thoracic Surgery, 1995
- Risks of Anticoagulant Therapy in Pregnant Women with Artificial Heart ValvesNew England Journal of Medicine, 1986